Cargando…

Technical and clinical validation of the Allergen BioCube(®) for timothy grass

INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(®) using timothy gra...

Descripción completa

Detalles Bibliográficos
Autores principales: Angjeli, Endri, Gomes, Paul, Lane, Keith J., Stein, Linda, Abelson, Mark B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322160/
https://www.ncbi.nlm.nih.gov/pubmed/28250927
http://dx.doi.org/10.1002/iid3.143
_version_ 1782509798137266176
author Angjeli, Endri
Gomes, Paul
Lane, Keith J.
Stein, Linda
Abelson, Mark B.
author_facet Angjeli, Endri
Gomes, Paul
Lane, Keith J.
Stein, Linda
Abelson, Mark B.
author_sort Angjeli, Endri
collection PubMed
description INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(®) using timothy grass to confirm uniform allergen concentration and clinically relevant subject symptom responses. METHODS: Allergen concentrations were verified by laser particle counts. Subjects (N = 14) with positive skin test reactions and no symptoms at screening received four 3‐h timothy grass exposures in the BioCube over consecutive days. Subjects evaluated nasal itching, sneezing, rhinorrhea, and nasal congestion while in the BioCube; Total Nasal Symptom Score (TNSS) was computed. Peak Nasal Inspiratory Flow (PNIF), Peak Expiratory Flow Rate (PEFR), sIgE blood tests, and Nasal Inflammation Score (NIS) were assessed. A correlation analysis was conducted for mean sIgE, skin test, and TNSS. RESULTS: Uniform timothy grass concentrations were achieved in the BioCube, both spatially and temporally, at all subject positions. Mean TNSS increased substantially from pre‐exposure levels (0.36 ± 0.74 to 1.86 ± 2.14) to maximums of 7.07 ± 2.76 at 1.5 h and 6.71 ± 2.70 at 3 h BioCube exposure. Twelve (86%) subjects had TNSS increases ≥6 units. PNIF decreased 12–24% from baseline at 3‐h BioCube exposure. NIS increased (baseline = 0) to 3.7 (maximum score = 4). A low/moderate correlation (r = 0.485) occurred between mean sIgE blood levels and mean skin tests; neither sIgE or skin tests correlated with mean TNSS. However, subjects with high skin test scores or positive blood IgE tended to also have higher TNSS. CONCLUSIONS: The Allergen BioCube achieved technical and clinical validation for uniform timothy grass concentration and clinically meaningful AR sign and symptom responses. The Allergen BioCube can be used to assess the efficacy of therapies for reduction of AR signs and symptoms resulting from grass exposure.
format Online
Article
Text
id pubmed-5322160
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-53221602017-03-01 Technical and clinical validation of the Allergen BioCube(®) for timothy grass Angjeli, Endri Gomes, Paul Lane, Keith J. Stein, Linda Abelson, Mark B. Immun Inflamm Dis Original Research INTRODUCTION: Field studies for allergic rhinitis (AR) commonly have inconsistent allergen concentrations and subject exposure patterns due to varying environmental conditions and subject behaviors. A technical and clinical validation study was conducted for the Allergen BioCube(®) using timothy grass to confirm uniform allergen concentration and clinically relevant subject symptom responses. METHODS: Allergen concentrations were verified by laser particle counts. Subjects (N = 14) with positive skin test reactions and no symptoms at screening received four 3‐h timothy grass exposures in the BioCube over consecutive days. Subjects evaluated nasal itching, sneezing, rhinorrhea, and nasal congestion while in the BioCube; Total Nasal Symptom Score (TNSS) was computed. Peak Nasal Inspiratory Flow (PNIF), Peak Expiratory Flow Rate (PEFR), sIgE blood tests, and Nasal Inflammation Score (NIS) were assessed. A correlation analysis was conducted for mean sIgE, skin test, and TNSS. RESULTS: Uniform timothy grass concentrations were achieved in the BioCube, both spatially and temporally, at all subject positions. Mean TNSS increased substantially from pre‐exposure levels (0.36 ± 0.74 to 1.86 ± 2.14) to maximums of 7.07 ± 2.76 at 1.5 h and 6.71 ± 2.70 at 3 h BioCube exposure. Twelve (86%) subjects had TNSS increases ≥6 units. PNIF decreased 12–24% from baseline at 3‐h BioCube exposure. NIS increased (baseline = 0) to 3.7 (maximum score = 4). A low/moderate correlation (r = 0.485) occurred between mean sIgE blood levels and mean skin tests; neither sIgE or skin tests correlated with mean TNSS. However, subjects with high skin test scores or positive blood IgE tended to also have higher TNSS. CONCLUSIONS: The Allergen BioCube achieved technical and clinical validation for uniform timothy grass concentration and clinically meaningful AR sign and symptom responses. The Allergen BioCube can be used to assess the efficacy of therapies for reduction of AR signs and symptoms resulting from grass exposure. John Wiley and Sons Inc. 2017-02-02 /pmc/articles/PMC5322160/ /pubmed/28250927 http://dx.doi.org/10.1002/iid3.143 Text en © 2017 The Authors. Immunity, Inflammation and Disease Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution (http://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Research
Angjeli, Endri
Gomes, Paul
Lane, Keith J.
Stein, Linda
Abelson, Mark B.
Technical and clinical validation of the Allergen BioCube(®) for timothy grass
title Technical and clinical validation of the Allergen BioCube(®) for timothy grass
title_full Technical and clinical validation of the Allergen BioCube(®) for timothy grass
title_fullStr Technical and clinical validation of the Allergen BioCube(®) for timothy grass
title_full_unstemmed Technical and clinical validation of the Allergen BioCube(®) for timothy grass
title_short Technical and clinical validation of the Allergen BioCube(®) for timothy grass
title_sort technical and clinical validation of the allergen biocube(®) for timothy grass
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5322160/
https://www.ncbi.nlm.nih.gov/pubmed/28250927
http://dx.doi.org/10.1002/iid3.143
work_keys_str_mv AT angjeliendri technicalandclinicalvalidationoftheallergenbiocubefortimothygrass
AT gomespaul technicalandclinicalvalidationoftheallergenbiocubefortimothygrass
AT lanekeithj technicalandclinicalvalidationoftheallergenbiocubefortimothygrass
AT steinlinda technicalandclinicalvalidationoftheallergenbiocubefortimothygrass
AT abelsonmarkb technicalandclinicalvalidationoftheallergenbiocubefortimothygrass